Characterization of agonist-induced vasoconstriction in mouse pulmonary artery

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 1, 2008, Pages

  Xu, Minlin ^a   Platoshyn, Oleksandr ^a   Makino, Ayako ^a   Dillmann, Wolfgang H ^a   Akassoglou, Katerina ^b   Remillard, Carmelle V ^a   Yuan, Jason X J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Excitation contraction coupling; G protein coupled receptors; Pharmacology; Store depletion

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCHOLINE; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; POTASSIUM; SEROTONIN; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; BLOOD VESSEL REACTIVITY; CALCIUM TRANSPORT; CELL STIMULATION; CONTROLLED STUDY; EXCITATION CONTRACTION COUPLING; LUNG DISEASE; LUNG VASOCONSTRICTION; MALE; MEMBRANE DEPOLARIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; VASOCONSTRICTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; 4-AMINOPYRIDINE; ACETYLCHOLINE; ADRENERGIC ALPHA-AGONISTS; ANIMALS; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; MALE; MEMBRANE POTENTIALS; MICE; MICE, INBRED BALB C; PHENYLEPHRINE; POTASSIUM; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; PULMONARY ARTERY; SEROTONIN; SPECIES SPECIFICITY; STRESS, MECHANICAL; THROMBIN; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS; VASOPRESSINS;

EID: 38149077193     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00968.2007     Document Type: Article

References (72)

1. Bennie RE, Packer CS, Powell DR, Jin N, Rhoades RA. Biphasic contractile response of pulmonary artery to hypoxia. Am J Physiol Lung Cell Mol Physiol 261: L156-L163, 1991.
2. Brusselmans K, Compernolle V, Tjwa M, Wiesener MS, Maxwell PH, Collen D, Carmeliet P. Heterozygous deficiency of hypoxia-inducible factor-2α protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest 111: 1519-1527, 2003.
3. Busse R, Edwards G, Félétou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci 23: 374-380, 2002.
4. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78: 415-423, 1996.
5. Champion HC, Bivalacqua TJ, Toyoda K, Heistad DD, Hyman AL, Kadowitz PJ. In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. Circulation 101: 923-930, 2000.
6. Chataigneau T, Félétou M, Huang PL, Fishman MC, Duhault J, Vanhoutte PM. Acetylcholine-induced relaxation in blood vessels from endothelial nitric oxide synthase knockout mice. Br J Pharmacol 126: 219-226, 1999.
7. Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol 95: 1165-1174, 1988.
8. Chen YF, Oparil S. Endothelin and pulmonary hypertension. J Cardiovasc Pharmacol 35: S49-S53, 2000.
9. 2- adrenergic receptors. Mol Pharmacol 60: 955-962, 2001.
10. + channels and pulmonary vasoconstriction. Role of protein kinase Cζ. Circ Res 93: 656-663, 2003.
11. Demiryurek AT, Wadsworth RM, Kane KA. Effects of hypoxia on isolated intrapulmonary arteries from the sheep. Pulm Pharmacol 4: 158-164, 1991.
12. -/- mice. Mol Cell Biol 25: 6980-6989, 2005.
13. Doggrell SA, Wanstall JC, Gambino A. Functional effects of 4-aminopyridine (4-AP) on pulmonary and systemic vessels from normoxic control and hypoxic pulmonary hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol 360: 317-323, 1999.
14. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 396: 269-272, 1998.
15. Eichinger MR, Walker BR. Enhanced pulmonary arterial dilation to arginine vasopressin in chronically hypoxic rats. Am J Physiol Heart Circ Physiol 267: H2413-H2419, 1994.
16. Eichinger MR, Walker BR. Segmental heterogeneity of NO-mediated pulmonary vasodilation in rats. Am J Physiol Heart Circ Physiol 267: H494-H499, 1994.
17. Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 103: 1241-1245, 1993.
18. Fagan KA, Tyler RC, Sato K, Fouty BW, Morris KG Jr, Huang PL, McMurtry IF, Rodman DM. Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. Am J Physiol Lung Cell Mol Physiol 277: L472-L478, 1999.
19. Frank DB, Abtahi A, Yamaguchi DJ, Manning S, Shyr Y, Pozzi A, Baldwin HS, Johnson JE, de Caestecker MP. Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. Circ Res 97: 496-504, 2005.
20. Fung YC. What principle governs the stress distribution in living organisms. In: Biomechanics in China, Japan, and U.S.A., edited by Fung YC. Beijing, China: Science Press, 1983, p. 1-13.
21. Glusa E, Bretschneider E, Paintz M. Contractile effects of thrombin in porcine pulmonary arteries and the influence of thrombin inhibitors. Naunyn Schmiedebergs Arch Pharmacol 349: 101-106, 1994.
22. 2+ pump blockers: thapsigargin and cyclopiazonic acid. Pflügers Arch 429: 617-624, 1995.
23. 2-deficient mice. Br J Pharmacol 147: 569-574, 2006.
24. Hamilton JR, Moffatt JD, Frauman AG, Cocks TM. Protease-activated receptor (PAR) 1 but not PAR2 or PAR4 mediates endothelium-dependent relaxation to thrombin and trypsin in human pulmonary arteries. J Cardiovasc Pharmacol 38: 108-119, 2001.
25. Horgan MJ, Pinheiro JMB, Malik AB. Mechanism of endothelin-1-induced pulmonary vasoconstriction. Circ Res 69: 157-164, 1991.
26. Horváth B, Orsy P, Benyó Z. Endothelial NOS-mediated relaxations of isolated thoracic aorta of the C57BL/6J mouse: a methodological study. J Cardiovasc Pharmacol 45: 225-231, 2005.
27. Huang W, Yen RT. Zero-stress states of human pulmonary arteries and veins. J Appl Physiol 85: 867-873, 1998.
28. Izumi N, Mizuguchi S, Inagaki Y, Saika S, Kawada N, Nakajima Y, Inoue K, Suehiro S, Friedman SL, Ikeda K. BMP-7 opposes TGF-β1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am J Physiol Lung Cell Mol Physiol 290: L120-L126, 2006.
29. Janssens WJ, Verhaeghe RH. Effect of thrombin on isolated canine blood vessels. Blood Vessels 19: 126-134, 1982.
30. Joshi S, Balan P, Gurney AM. Pulmonary vasoconstrictor action of KCNQ potassium channel blockers. Respir Res 7: 31-40, 2006.
31. 2+ entry. Am J Physiol Lung Cell Mol Physiol 287: L962-L969, 2004.
32. Launay JM, Hervé P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8: 1129-1135, 2002.
33. Lawrence RN, Clelland C, Beggs D, Salama FD, Dunn WR, Wilson VG. Differential role of vasoactive prostanoids in porcine and human isolated pulmonary arteries in response to endothelium-dependent relaxants. Br J Pharmacol 125: 1128-1137, 1998.
34. Lawrie A, Spiekerkoetter E, Martinez EC, Ambartsumian N, Sheward WJ, MacLean MR, Harmar AJ, Schmidt AM, Lukanidin E, Rabinovitch M. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res 97: 227-235, 2005.
35. Le Cras TD, Hardie WD, Fagan K, Whitsett JA, Korfhagen TR. Disrupted pulmonary vascular development and pulmonary hypertension in transgenic mice overexpressing transforming growth factor-α. Am J Physiol Lung Cell Mol Physiol 285: L1046-L1054, 2003.
36. phox. Chest 128: 594S-596S, 2005.
37. Liu JQ, Folz RJ. Extracellular superoxide enhances 5-HT-induced murine pulmonary artery vasoconstriction. Am J Physiol Lung Cell Mol Physiol 287: L111-L118, 2004.
38. phox). Am J Physiol Lung Cell Mol Physiol 290: L2-L10, 2006.
39. 2+-ATPase isoform 3. J Biol Chem 272: 30538-30545, 1997.
40. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X, Rudarakanchana N, Southwood M, James V, Trembath RC, Morrell NW. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 98: 818-827, 2006.
41. Lorenz JN, Arend LJ, Robitz R, Paul RJ, MacLennan AJ. Vascular dysfunction in S1P2 sphingosine 1-phosphate receptor knockout mice. Am J Physiol Regul Integr Comp Physiol 292: R440-R446, 2007.
42. MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, Morecroft I. 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 119: 917-930, 1996.
43. Madden JA, Vadula KS, Kurup VP. Effects of hypoxia and other vasoactive agents on pulmonary and cerebral artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 263: L384-L393, 1992.
44. 2+ entry in agonist-induced pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol 280: L870-L880, 2001.
45. Morecroft I, Dempsie Y, Bader M, Walther DJ, Kotnik K, Loughlin L, Nilsen M, MacLean MR. Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 49: 232-236, 2007.
46. 2+ influx and contraction in rat pulmonary artery. Circ Res 89: 923-929, 2001.
47. Ozaki M, Kawashima S, Yamashita T, Ohashi Y, Rikitake Y, Inoue N, Hirata KI, Hayashi Y, Itoh H, Yokoyama M. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium. Hypertension 37: 322-327, 2001.
48. Perlegas D, Xie H, Sinha S, Somlyo AV, Owens GK. ANG II type 2 receptor regulates smooth muscle growth and force generation in late fetal mouse development. Am J Physiol Heart Circ Physiol 288: H96-H102, 2005.
49. + exchange in pulmonary arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 289: L867-L874, 2005.
50. Sai Y, Okamura T, Amakata Y, Toda N. Comparison of responses of canine pulmonary artery and vein to angiotensin II, bradykinin and vasopressin. Eur J Pharmacol 282: 235-241, 1995.
51. Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ, Jiang YP, Chen JJ, Waschek JA, Kort S. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 115: 1260-1268, 2007.
52. Sauzeau V, Rolli-Derkinderen M, Lehoux S, Loirand G, Pacaud P. Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery. Circ Res 93: 630-637, 2003.
53. Schmidt D, Rühlmann E, Waldeck B, Branscheid D, Luts A, Sundler F, Rabe K. The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery. Naunyn Schmiedebergs Arch Pharmacol 364: 314-320, 2001.
54. +-induced membrane depolarization attenuates endothelium-dependent pulmonary vasodilation. Am J Physiol Lung Cell Mol Physiol 278: L261-L267, 2000.
55. + currents by endothelin-1 in human pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol 281: L1115-L1122, 2001.
56. Somlyo AP, Somlyo AV. Smooth muscle: excitation-contraction coupling, contractile regulation, and the cross-bridge cycle. Alcohol Clin Exp Res 18: 138-143, 1994.
57. Steudel W, Ichinose F, Huang PL, Hurford WE, Jones RC, Bevan JA, Fishman MC, Zapol WM. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res 81: 34-41, 1997.
58. Swafford AN Jr, Harrison-Bernard LM, Dick GM. Knockout mice reveal that the angiotensin II type 1B receptor links to smooth muscle contraction. Am J Hypertens 20: 335-337, 2007.
59. Vaishnav RN, Vossoughi J. Estimation of residual strains in aortic segments. In: Biomedical Engineering. II. Recent Developments, edited by Hall CW. New York: Pergammon, 1983, p. 330-333.
60. Wanstall JC, O'Donnell SR. Endothelin and 5-hydroxytryptamine on rat pulmonary artery in pulmonary hypertension. Eur J Pharmacol 176: 159-168, 1990.
61. Wanstall JC, O'Donnell SR. Endothelin-induced contractions of rat pulmonary artery are not affected by drugs acting on potassium channels. J Pharm Pharmacol 43: 739-741, 1991.
62. West J, Fagan K, Steudel W, Fouty B, Lane K, Harral J, Hoedt-Miller M, Tada Y, Ozimek J, Tuder R, Rodman DM. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 94: 1109-1114, 2004.
63. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JSK, Wiener CM, Sylvester JT, Semenza GL. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α. J Clin Invest 103: 691-696, 1999.
64. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98: 1400-1406, 1998.
65. i in pulmonary arterial myocytes. Circ Res 77: 370-378, 1995.
66. Yuan XJ, Tod ML, Rubin LJ, Blaustein MP. Contrasting effects of hypoxia on tension in rat pulmonary and mesenteric arteries. Am J Physiol Heart Circ Physiol 259: H281-H289, 1990.
67. Zaidi SHE, You XM, Ciura S, Husain M, Rabinovitch M. Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 105: 516-521, 2002.
68. Ca channels antagonizes NO-induced relaxation in pulmonary artery. Am J Physiol Heart Circ Physiol 272: H904-H912, 1997.
69. Zhao YJ, Wang J, Tod ML, Rubin LJ, Yuan XJ. Pulmonary vasoconstrictor effects of prostacyclin in rats: potential role of thromboxane receptors. J Appl Physiol 81: 2595-2603, 1996.
70. 2+ release and contraction in pulmonary artery myocytes. Cell Calcium 35: 345-355, 2004.
71. Zhou Y, Chen Y, Dirksen WP, Morris M, Periasamy M. AT1b receptor predominantly mediates contractions in major mouse blood vessels. Circ Res 93: 1089-1094, 2003.
72. Zhou Y, Varadharaj S, Zhao X, Parinandi N, Flavahan NA, Zweier JL. Acetylcholine causes endothelium-dependent contraction of mouse arteries. Am J Physiol Heart Circ Physiol 289: H1027-H1032, 2005.